KRAS and cancer: Notably, the synergy occurred across a wide dose range of AZD4547 and BI2536 in KRAS‐mutant lung and pancreatic (H358, H441, A549, and MIAPaCa‐2), but not in KRAS‐mutant colon (SW620, DLD‐1) nor KRAS‐WT lung (EBC‐1, H1993) cancer cells (Appendix Fig S2C).